TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20027405

Group type: EXPERIMENTAL
Intervention: 90 mg etoricoxib
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Dipyrone
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 16483659

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.3 mg
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Number of subjects: 64

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 64
Study: 15208594

Group type: EXPERIMENTAL
Intervention: Amphotericin B (200 microL per nostril, 3 mg/mL, 4 times daily for 8 weeks)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control (saline nasal spray, 4 times daily for 8 weeks)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Amphotericin B
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control
Number of subjects: 78
Study: 10096692

Group type: EXPERIMENTAL
Intervention: IgE response to Timothy grass pollen measured by the RAST test
Number of subjects: 234

Group type: COMPARATOR
Intervention: Broad and narrow definitions of SRA phenotypes
Number of subjects: 234
Study: 7495975

Group type: EXPERIMENTAL
Intervention: High-purity factor VIII preparations (ion-exchange S/D step)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Monoclonal antibody factor VIII preparations
Number of subjects: 0
Study: 2139833

Group type: EXPERIMENTAL
Intervention: tiadenol
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: simvastatin
Number of subjects: 40
Study: 6990858

Group type: EXPERIMENTAL
Intervention: Intravenous cholegraphy (IVC)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Oral cholecystography (OCC)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Ultrasonography (US)
Number of subjects: 67
Study: 31394601

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen treatment
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 71
Study: 27785586

Group type: EXPERIMENTAL
Intervention: Partial removable dental prosthesis (PRDP)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Shortened dental arch (SDA) concept
Number of subjects: 91
Study: 24811226

Group type: EXPERIMENTAL
Intervention: Nitroglycerin (NG) dermal patch
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 0
Study: 22370697

Group type: EXPERIMENTAL
Intervention: Web-based smoking cessation intervention (PFH-2)
Number of subjects: 2005
Study: 20849685

Group type: EXPERIMENTAL
Intervention: Repeated sensitisation using clinical vignettes at 1, 3, and 5 months
Number of subjects: 1138

Group type: COMPARATOR
Intervention: No sensitisation
Number of subjects: 1138
Study: 17992715

Group type: EXPERIMENTAL
Intervention: Formula containing LCPUFA (arachidonic and docosahexaenoic) (group A, n = 50)
Number of subjects: 104

Group type: COMPARATOR
Intervention: LCPUFA‐free formula (group B, n = 54)
Number of subjects: 104
Study: 16304259

Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT) for 1 year
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (very low load training)
Number of subjects: 42
Study: 12085255

Group type: EXPERIMENTAL
Intervention: Aspirin use (three or more times per week for at least 6 months)
Number of subjects: 81

Group type: COMPARATOR
Intervention: No aspirin use
Number of subjects: 81
Study: 10213219

Group type: EXPERIMENTAL
Intervention: Serial measurements of PSA, hemoglobin, and weight
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Prognostic score based on PSA, hemoglobin, and weight
Number of subjects: 348
Study: 7608257

Group type: EXPERIMENTAL
Intervention: GH 1 IU/m2.day
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: GH 2 IU/m2.day
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: GH 3 IU/m2.day
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: GH 0.33 IU/m2.day
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: GH < 0.67 IU/m2.day
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: GH 1.10 IU/m2.day
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 2132273

Group type: EXPERIMENTAL
Intervention: 1.5% oral benzydamine spray applied six times per day (four sprays per application) for five days
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 7398470

Group type: EXPERIMENTAL
Intervention: Neomycin/Bacitracin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clindamycin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of Neomycin/Bacitracin and Clindamycin
Number of subjects: 0
Study: 30296614

Group type: EXPERIMENTAL
Intervention: Experimental sensorimotor incongruence (SMI) induced via distorting visual feedback during movement
Number of subjects: 66

Group type: COMPARATOR
Intervention: Static visual feedback
Number of subjects: 66
Study: 28809724

Group type: EXPERIMENTAL
Intervention: QuikClot Radial pad (30 min compression)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: QuikClot Radial pad (60 min compression)
Number of subjects: 30

Group type: COMPARATOR
Intervention: TR Band (mechanical compression)
Number of subjects: 30
Study: 26418025

Group type: EXPERIMENTAL
Intervention: PFO closure
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no PFO closure)
Number of subjects: 40
Study: 24494277

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with auricular point sticking therapy (group A)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Clomiphene oral administration (group B)
Number of subjects: 100
Study: 22045822

Group type: EXPERIMENTAL
Intervention: Faecal immunochemical test (FIT)
Number of subjects: 11632

Group type: COMPARATOR
Intervention: Guaiac faecal occult blood test (gFOBT)
Number of subjects: 11632

Group type: EXPERIMENTAL
Intervention: Overall test uptake (comparing FIT and gFOBT)
Number of subjects: 11632
Study: 19270248

Group type: EXPERIMENTAL
Intervention: Panic‐Focused Psychodynamic Psychotherapy (PFPP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Applied Relaxation Training (ART)
Number of subjects: 0
Study: 17218230

Group type: EXPERIMENTAL
Intervention: Pentoxifylline 800 mg daily for 6 months
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 88
Study: 16503940

Group type: EXPERIMENTAL
Intervention: Birch bark ointment only
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Combination therapy with cryotherapy and birch bark ointment
Number of subjects: 28
Study: 12717217

Group type: EXPERIMENTAL
Intervention: WOFIE protocol (immunosuppression stopped for 72 hr posttransplant)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (standard immunosuppression without WOFIE)
Number of subjects: 30
Study: 10733053

Group type: EXPERIMENTAL
Intervention: Biofeedback-based, computerized intervention
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study: 8963651

Group type: EXPERIMENTAL
Intervention: 0.5 mg melatonin administered orally 60 min prior to the light pulse
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo administered orally 60 min prior to the light pulse
Number of subjects: 6
Study: 1854430

Group type: EXPERIMENTAL
Intervention: Specific immunotherapy using the alpha-fraction of D. pteronyssinus
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 0
Study: 6178347

Group type: EXPERIMENTAL
Intervention: Bupivacaine with high-molecular-weight dextran and adrenaline
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Bupivacaine with high-molecular-weight dextran without adrenaline
Number of subjects: 40

Group type: COMPARATOR
Intervention: Bupivacaine with saline
Number of subjects: 40
Study: 30121721

Group type: EXPERIMENTAL
Intervention: LED phototherapy (180 mW, 22 s, 4 J, 8 J/cm2, 0.36 W/cm2, spot of 0.5 cm2, spot diameter 0.8 cm)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (not irradiated)
Number of subjects: 40
Study: 28802882

Group type: EXPERIMENTAL
Intervention: Ketamine infusion (0.05 mg/kg)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Ketamine infusion (0.05 mg/kg) in opioid-naive subjects
Number of subjects: 4

Group type: COMPARATOR
Intervention: Saline placebo in chronic opioid users
Number of subjects: 4
Study: 26007637

Group type: EXPERIMENTAL
Intervention: Kv7.2(A294V) mutation
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Kv7.2(A294V) with Kv7.3 subunit
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Kv7.2(A294V)/Kv7.2/Kv7.3 configuration
Number of subjects: 7

Group type: COMPARATOR
Intervention: Kv7.2(A294G) mutation
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: p.A294V mutation in neurons
Number of subjects: 7

Group type: COMPARATOR
Intervention: p.A294G mutation in neurons
Number of subjects: 7
Study: 23846316

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/vilanterol (FF/VI) 100/25 μg once daily
Number of subjects: 806

Group type: COMPARATOR
Intervention: Fluticasone propionate/salmeterol (FP/SAL) 250/50 μg bid
Number of subjects: 806

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 806
Study: 21672495

Group type: EXPERIMENTAL
Intervention: Verum electroacupuncture (12 sessions of 30 minutes each over 6 to 8 weeks)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control acupuncture (needling at nonchannel scalp points with sham electrostimulation, 12 sessions of 30 minutes each over 6 to 8 weeks)
Number of subjects: 53
Study: 19843784

Group type: EXPERIMENTAL
Intervention: IV lidocaine
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo (saline infusion)
Number of subjects: 65
Study: 17202945

Group type: COMPARATOR
Intervention: Prednisolone
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Prednisolone-valacyclovir
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Both groups (prednisolone and prednisolone-valacyclovir)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Age groups and paralysis status
Number of subjects: 150
Study: 14704645

Group type: EXPERIMENTAL
Intervention: Bio-Hep-B vaccine (2.5 microg)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Bio-Hep-B vaccine (5 microg)
Number of subjects: 28
Study: 11684212

Group type: EXPERIMENTAL
Intervention: Daily rhDNase (2.5 mg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Alternate-day rhDNase (2.5 mg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Hypertonic saline (5 mL 7%)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Daily rhDNase vs Hypertonic saline
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Daily rhDNase vs Alternate-day rhDNase
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Cost comparison
Number of subjects: 48
Study: 9596315

Group type: EXPERIMENTAL
Intervention: Aerosolized recombinant human DNase I (rhDNase)
Number of subjects: 349

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 349
Study: 7833220

Group type: EXPERIMENTAL
Intervention: Icatibant 20 micrograms kg‐1
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Icatibant 50 micrograms kg‐1
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Icatibant 100 micrograms kg‐1
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 3279488

Group type: EXPERIMENTAL
Intervention: Quinolones (ciprofloxacin, enoxacin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quinolones (ciprofloxacin)
Number of subjects: 0
Study: 31815661

Group type: EXPERIMENTAL
Intervention: Vitamin D and omega-3 fatty acids co-supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27613885

Group type: EXPERIMENTAL
Intervention: Reduced-nicotine content (RNC) cigarettes
Number of subjects: 717

Group type: COMPARATOR
Intervention: Normal-nicotine content (NNC) cigarettes
Number of subjects: 717
Study: 25886825

Group type: EXPERIMENTAL
Intervention: Hinged soft knee orthosis
Number of subjects: 31
Study: 24053480

Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg/day + Rosuvastatin 2.5 mg/day (combination group)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Rosuvastatin 5 mg/day (dose escalation group)
Number of subjects: 79
Study: 21631570

Group type: EXPERIMENTAL
Intervention: Repaglinide (1 mg, three times daily) for 8 weeks
Number of subjects: 170
Study: 19124121

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 4444

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4444
Study: 17942387

Group type: EXPERIMENTAL
Intervention: Internet questionnaire
Number of subjects: 533

Group type: COMPARATOR
Intervention: Paper-and-pencil questionnaire
Number of subjects: 533
Study: 15482352

Group type: EXPERIMENTAL
Intervention: Zolmitriptan 2.5 mg
Number of subjects: 280
Study: 12661619

Group type: EXPERIMENTAL
Intervention: Videoconferencing for discharge planning
Number of subjects: 204

Group type: COMPARATOR
Intervention: Face-to-face meetings for discharge planning
Number of subjects: 204
Study: 10195339

Group type: EXPERIMENTAL
Intervention: Patients with neurological symptoms
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Patients without neurological symptoms
Number of subjects: 13

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Longer duration of disease
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: More severe cognitive deficits
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: More pronounced psychiatric symptoms
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: More pronounced motor disabilities
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: More pronounced psychiatric symptoms and cognitive deficits
Number of subjects: 13
Study: 8645847

Group type: EXPERIMENTAL
Intervention: Amphotericin B bladder irrigation (AmBBI) at 50 mg/L over 24 hours or 50 mg/L for 7 days
Number of subjects: 53

Group type: COMPARATOR
Intervention: Oral fluconazole at 200 mg/d for 7 days
Number of subjects: 53
Study: 2140996

Group type: EXPERIMENTAL
Intervention: Nafarelin 400 micrograms daily
Number of subjects: 82

Group type: COMPARATOR
Intervention: Danazol 600 mg daily
Number of subjects: 82
Study: 493514

Group type: EXPERIMENTAL
Intervention: Simethicone
Number of subjects: 169

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 169
Study: 31600790

Group type: EXPERIMENTAL
Intervention: Conservative treatment for PDA
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control cohort (standard treatment)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Conservative cohort
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control cohort
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: PDA >28 days
Number of subjects: 83
Study: 30408001

Group type: EXPERIMENTAL
Intervention: Hexavalent vaccine (DTaP‐IPV‐HB‐PRP‐T) at 2 and 6 months, Pentavalent vaccine (DTaP‐IPV//PRP‐T) at 4 months
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Booster vaccination (DTaP‐IPV//PRP‐T and pneumococcal vaccine) at 18 months
Number of subjects: 265
Study: 28116506

Group type: EXPERIMENTAL
Intervention: Epidural block (Epi) using ropivacaine
Number of subjects: 72

Group type: COMPARATOR
Intervention: Paravertebral block via the surgical field (PVB-sf) using ropivacaine
Number of subjects: 72
Study: 26002986

Group type: EXPERIMENTAL
Intervention: Robotic surgery (group C)
Number of subjects: 526

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery (group B)
Number of subjects: 526

Group type: COMPARATOR
Intervention: Abdominal surgery (group A)
Number of subjects: 526

Group type: COMPARATOR
Intervention: All groups (A, B, C)
Number of subjects: 526
Study: 24165255

Group type: EXPERIMENTAL
Intervention: Continuous vancomycin infusion (CVI)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Intermittent vancomycin infusion (IVI)
Number of subjects: 73
Study: 21386830

Group type: EXPERIMENTAL
Intervention: Zoledronate (4 mg intravenous), n=20
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo, n=20
Number of subjects: 40

Group type: COMPARATOR
Intervention: Comparison of ZOL vs. Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Zoledronate (4 mg intravenous)
Number of subjects: 40
Study: 19564877

Group type: EXPERIMENTAL
Intervention: diethylpropion 50 mg BID
Number of subjects: 69

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: diethylpropion (after switching from placebo)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: diethylpropion
Number of subjects: 69

Group type: COMPARATOR
Intervention: diethylpropion and placebo
Number of subjects: 69
Study: 17178091

Group type: EXPERIMENTAL
Intervention: Frequency-doubling perimetry (FDP)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Standard automated perimetry (SAP)
Number of subjects: 92
Study: 14745664

Group type: EXPERIMENTAL
Intervention: Apple-pectin powder (15-16% pectin)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo powder
Number of subjects: 64
Study: 11736720

Group type: EXPERIMENTAL
Intervention: Thymosin
Number of subjects: 353

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 353
Study: 9332683

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy (XRT group)
Number of subjects: 381

Group type: COMPARATOR
Intervention: No postoperative radiotherapy (non-XRT group)
Number of subjects: 381
Study: 8466064

Group type: COMPARATOR
Intervention: Balanced anesthesia (nitrous oxide in 40% oxygen supplemented with fentanyl, thiopental, and droperidol)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Enflurane-nitrous oxide (1.25 MAC)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Isoflurane-nitrous oxide (1.25 MAC)
Number of subjects: 30
Study: 3956211

Group type: EXPERIMENTAL
Intervention: Mexiletine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31468503

Group type: EXPERIMENTAL
Intervention: Ulipristal acetate (UPA)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Gonadotropin-releasing hormone agonists (GnRHa)
Number of subjects: 55
Study: 30192695

Group type: EXPERIMENTAL
Intervention: Ubiquinol (150 mg/day)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 27927936

Group type: EXPERIMENTAL
Intervention: Systolic Blood Pressure (SBP) ≥160 mm Hg
Number of subjects: 20332

Group type: EXPERIMENTAL
Intervention: Diastolic Blood Pressure (DBP) ≥100 mm Hg
Number of subjects: 20332

Group type: EXPERIMENTAL
Intervention: Increasing SBP and DBP categories
Number of subjects: 20332

Group type: EXPERIMENTAL
Intervention: Overall BP levels
Number of subjects: 20332
Study: 25548848

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23426761

Group type: EXPERIMENTAL
Intervention: Ketoconazole 400 mg QD for 28 days
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Rifampin 600 mg QD for 28 days
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo QD for 28 days
Number of subjects: 36
Study: 21420111

Group type: EXPERIMENTAL
Intervention: Tanezumab (200 μg/kg, single intravenous dose)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Tanezumab
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 20210207

Group type: EXPERIMENTAL
Intervention: Biocomplexes
Number of subjects: 0
Study: 17710125

Group type: EXPERIMENTAL
Intervention: FFM ME-TRAP
Number of subjects: 405

Group type: COMPARATOR
Intervention: Control (rabies vaccine)
Number of subjects: 405
Study: 15531052

Group type: EXPERIMENTAL
Intervention: Females
Number of subjects: 24

Group type: COMPARATOR
Intervention: Males
Number of subjects: 24
Study: 11587610

Group type: EXPERIMENTAL
Intervention: Ropivacaine
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Ropivacaine plus clonidine
Number of subjects: 64

Group type: COMPARATOR
Intervention: Isotonic sodium chloride
Number of subjects: 64
Study: 9296641

Group type: EXPERIMENTAL
Intervention: Fluvastatin 40 mg per day for 8 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 8295879

Group type: EXPERIMENTAL
Intervention: pirazinamid administered at a single dose daily or each other day
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: multicomponent form tricox (Jemis, India) with isoniazid, rifampicin, and pirazinamid
Number of subjects: 310
Study: 3726454

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of neurotensin in relevant doses
Number of subjects: 17

Group type: COMPARATOR
Intervention: Test meal
Number of subjects: 17
Study: 2568849

Group type: EXPERIMENTAL
Intervention: Combination of atracurium 0.125 mg kg‐1 + vecuronium 0.025 mg kg‐1
Number of subjects: 30

Group type: COMPARATOR
Intervention: Atracurium 0.5 mg kg‐1
Number of subjects: 30

Group type: COMPARATOR
Intervention: Vecuronium 0.1 mg kg‐1
Number of subjects: 30
Study: 31087419

Group type: EXPERIMENTAL
Intervention: Motivational-volitional group intervention (MoVo) consisting of four group sessions (60 min each)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Standard rehabilitation (control group)
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Motivational-volitional group intervention (MoVo)
Number of subjects: 800
Study: 28868633

Group type: EXPERIMENTAL
Intervention: Pimecrolimus 1% cream (PIM)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Low‐to‐medium‐potency topical corticosteroids (TCS)
Number of subjects: 100
Study: 27108464

Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural (CSE) with 0.5% heavy bupivacaine 2.5 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Low-dose epidural with 10ml of 0.1% bupivacaine and 2 µg/ml fentanyl
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural (CSE)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Low-dose epidural
Number of subjects: 60
Study: 23958597

Group type: EXPERIMENTAL
Intervention: High protein diet (30% protein [110 g/day], 40% carbohydrates [150 g/day], 30% fat [50 g/day])
Number of subjects: 61

Group type: COMPARATOR
Intervention: Standard protein diet (15% protein [55 g/day], 55% carbohydrates [200 g/day], 30% fat [50 g/day])
Number of subjects: 61
Study: 21368076

Group type: EXPERIMENTAL
Intervention: Total hip arthroplasty
Number of subjects: 120

Group type: COMPARATOR
Intervention: Bipolar hemiarthroplasty
Number of subjects: 120
Study: 19702089

Group type: EXPERIMENTAL
Intervention: Huangban Bianxing Recipe (HBR) taken orally, one dose every day for 3 months
Number of subjects: 80

Group type: COMPARATOR
Intervention: Ginkgo leaf tablet (19.2 mg) taken thrice a day for 3 months
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Huangban Bianxing Recipe (HBR)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Ginkgo leaf tablet (19.2 mg)
Number of subjects: 80